ESMO 2024 preview – Summit and BioNTech battle again
The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.
The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.
While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.
The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?
HanchorBio’s HCB301 is among the latest industry projects beginning first-in-human trials.
After being burned by Point, Lilly is taking a slower approach with Radionetics.
Farletuzumab ecteribulin follows its parent MAb with a setback, spelling possible bad news for Sutro.
Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.